Pipeline & funding radarSample radarConfidential
ILLUSTRATIVEAI drug-discovery rounds, quarter23▲ +15%
ILLUSTRATIVEPhase moves in your areas14▲ +5
ILLUSTRATIVENew licensing deals9▲ +2
Threat ring
Pharma Abig pharma
Biotech Bfast follower
Pharma Cgeneric leader
Biotech Dplatform biotech
Startup Edigital therapeutics
Latest signals
2h agoPharma A published a positive Phase 3 readout
5h agoBiotech B's EMA submission was accepted
1d agoBiosimilar launched 30% below reference in DE
Suggested decisionBring the access dossier forward; brief KOLs before the Q1 congress cycle.Illustrative values. Your radar is built on your market.
PHARMA · LIFE SCI

Follow pipelines, deals and funding across your therapy areas.

The agent reads trial registries, pipeline updates, licensing deals and funding rounds. It tells BD and commercial teams which programmes and buyers are moving.

Signals we read
01Clinical trial registrations02Pipeline and phase changes03Licensing and partnership deals04Biotech funding rounds05Regulatory approvals06AI drug-discovery launches
What your teams get
Business developmentNew partners and licensing targets flagged as deals close.
CommercialNewly funded biotechs likely to need your services, ranked weekly.
StrategyRival pipelines and approvals tracked by therapy area.
Case 04: a monthly buying-signal radar on 991 AI drug-discovery companies for a global life-science supplier.
WHY NOW · PHARMA

Loss of exclusivity, the EU HTA Regulation and biotech dealmaking leave less time to respond to rivals.

Your radar's KPI board.

ILLUSTRATIVE · tuned to your market
Pipeline events17▲ +4this quarter
Trial readouts due6▲ +2next 90 days
Pricing & access moves11▲ +3EU markets, 90 days
KOL & congress mentions340▲ +21%last 60 days

Rival watchlist.

Ranked by threat to you
Rival
Threat
Latest move
When
Pharma ABig pharma
Positive Phase 3 readout
1d
Biotech BFast follower
EMA submission filed
3d
Pharma CGeneric leader
Biosimilar −30% in DE
5d
Biotech DPlatform biotech
Partnered with Pharma A
1w
Startup EDigital therapeutics
Raised a $60M Series B
2w

This week, as it landed.

live feed
  1. 08:50
    PipelineHigh

    Pharma A published a positive Phase 3 readout

    Trial registry
  2. Yesterday
    RegulationHigh

    Biotech B's EMA submission was accepted

    EMA notices
  3. Yesterday
    PricingMedium

    Biosimilar launched 30% below reference in DE

    Price lists
  4. Mon
    PartnershipsMedium

    Biotech D signed a licensing deal with Pharma A

    Press release
  5. Mon
    TalentLow

    Pharma C hiring 25 market-access roles

    Job postings
  6. Sun
    ScienceLow

    11 abstracts on your target at ESMO

    Congress programmes

The questions your leadership asks.

And the signals that answer them
QUESTION 01

Which rival trials could change our launch timeline?

Answered by
Trial registriesReadoutsCongress abstracts
QUESTION 02

Where are rivals winning reimbursement and access?

Answered by
HTA decisionsTendersPrice listings
QUESTION 03

Which biotechs should we partner with or acquire?

Answered by
Funding roundsPatentsLicensing deals

What each team gets.

Use cases by team
Team
Your agent watches
The team gets
Competitive intelligence
Dated pipeline changes by indication
Market access
A country access tracker compared with rivals
BD & licensing
A scored partner shortlist, refreshed weekly
Medical affairs
A brief on new evidence before field teams get asked

Hundreds of signals a week. Your teams get the few that matter.

Eight weeks in pharma · illustrative · tap a week
558signals read
27sent to your teams
6decisions made
< 1 hfrom signal to alert
066132W36W37W38W39W40W41W42W43
Signals read (by type)Sent to a team
W40 · the week that mattered
Read101
Relevant18
Sent to teams6
Decisions2
The signal that matteredClinical trial registrations

Pharma A published a positive Phase 3 readout

Routed to Competitive intelligence2 decisions that week
With your agentFlagged within the hour
WithoutSeen at the quarterly review

Where your agent reads in pharma.

More sources added on request

Science & pipeline

Trial registriesPublicationsCongress abstractsPatent filingsPreprints

Regulation & access

EMA & FDA noticesHTA decisionsPrice listsReimbursement registersTender notices

Market & reach

Press releasesDeal announcementsJob postingsKOL socialAI-assistant answers
MONDAY BRIEF · PHARMA07:00 · 1 page

Three moves that matter this week.

  1. Pharma A's readout moves its launch window ahead of yours by ~2 quarters.
  2. Biosimilar pricing in DE sets a new floor for 2027 tenders.
  3. KOL attention on your target rose 21% after ESMO.
SUGGESTED DECISION

Bring the access dossier forward; brief KOLs before the Q1 congress cycle.

Sourced · reviewed by your BounceWatch analyst

Your first 30 days.

From kickoff to a live radar
  1. Day 1

    Map

    We map your rivals, markets and sources with your team.

  2. Day 7

    Readout

    Your first ranked list of moves, each with its source.

  3. Day 14

    Radar live

    Your sector radar and alerts go live for each team.

  4. Day 30

    Review

    Your analyst tunes what it watches and sets the KPIs.

START WITH A READOUT

See your pharma radar filled with this month's moves.

10 rivals, 90 days of dated moves, delivered in 7 business days. Fully credited if you continue within 30 days.

Book a 7-day Readout

See every move first. Decide before your rivals do.

Pick your sector and we'll show you the radar your agent would build, filled with this month's moves in your market.

See your sector Book a 7-day Readout
  • Every claim sourcedDated and linked to the page it came from
  • Analyst-reviewedA person checks every brief and memo
  • Private by designYour questions never train another client's agent
  • Built in AmsterdamServing enterprise teams across Europe and beyond
Rival Readout10 rivals · 7 business days · €7,500, credited if you continueGet a free snapshotBook a 7-day Readout